WHO’s Strategic Advisory Group of Experts on Immunization endorsed transitioning the novel OPV type 2 vaccine (nOPV2) from initial to wider use under WHO Emergency Use Listing, following a review of safety and genetic stability data from mass immunization campaigns. The decision (announced October 11) marks the end of the vaccine’s initial use period and the removal of certain use criteria for countries affected by cVDPV2 outbreaks. Rollout of nOPV2 began in March; approximately 100 million doses have been administered to children across seven countries. An additional 16 countries have been verified as ready to use nOPV2 by GPEI while 17 other countries are preparing to use it. More nOPV2 campaigns are due to launch later this year, although supply of the vaccine is limited. GPEI
Menu